Literature DB >> 27557301

A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor.

W Jeffrey Elias1, Nir Lipsman1, William G Ondo1, Pejman Ghanouni1, Young G Kim1, Wonhee Lee1, Michael Schwartz1, Kullervo Hynynen1, Andres M Lozano1, Binit B Shah1, Diane Huss1, Robert F Dallapiazza1, Ryder Gwinn1, Jennifer Witt1, Susie Ro1, Howard M Eisenberg1, Paul S Fishman1, Dheeraj Gandhi1, Casey H Halpern1, Rosalind Chuang1, Kim Butts Pauly1, Travis S Tierney1, Michael T Hayes1, G Rees Cosgrove1, Toshio Yamaguchi1, Keiichi Abe1, Takaomi Taira1, Jin W Chang1.   

Abstract

BACKGROUND: Uncontrolled pilot studies have suggested the efficacy of focused ultrasound thalamotomy with magnetic resonance imaging (MRI) guidance for the treatment of essential tremor.
METHODS: We enrolled patients with moderate-to-severe essential tremor that had not responded to at least two trials of medical therapy and randomly assigned them in a 3:1 ratio to undergo unilateral focused ultrasound thalamotomy or a sham procedure. The Clinical Rating Scale for Tremor and the Quality of Life in Essential Tremor Questionnaire were administered at baseline and at 1, 3, 6, and 12 months. Tremor assessments were videotaped and rated by an independent group of neurologists who were unaware of the treatment assignments. The primary outcome was the between-group difference in the change from baseline to 3 months in hand tremor, rated on a 32-point scale (with higher scores indicating more severe tremor). After 3 months, patients in the sham-procedure group could cross over to active treatment (the open-label extension cohort).
RESULTS: Seventy-six patients were included in the analysis. Hand-tremor scores improved more after focused ultrasound thalamotomy (from 18.1 points at baseline to 9.6 at 3 months) than after the sham procedure (from 16.0 to 15.8 points); the between-group difference in the mean change was 8.3 points (95% confidence interval [CI], 5.9 to 10.7; P<0.001). The improvement in the thalamotomy group was maintained at 12 months (change from baseline, 7.2 points; 95% CI, 6.1 to 8.3). Secondary outcome measures assessing disability and quality of life also improved with active treatment (the blinded thalamotomy cohort)as compared with the sham procedure (P<0.001 for both comparisons). Adverse events in the thalamotomy group included gait disturbance in 36% of patients and paresthesias or numbness in 38%; these adverse events persisted at 12 months in 9% and 14% of patients, respectively.
CONCLUSIONS: MRI-guided focused ultrasound thalamotomy reduced hand tremor in patients with essential tremor. Side effects included sensory and gait disturbances. (Funded by InSightec and others; ClinicalTrials.gov number, NCT01827904.).

Entities:  

Mesh:

Year:  2016        PMID: 27557301     DOI: 10.1056/NEJMoa1600159

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  176 in total

Review 1.  Movement disorders in 2016: Progress in Parkinson disease and other movement disorders.

Authors:  Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2017-01-13       Impact factor: 42.937

2.  Predicting Bone Marrow Damage in the Skull After Clinical Transcranial MRI-Guided Focused Ultrasound With Acoustic and Thermal Simulations.

Authors:  Nathan McDannold; P Jason White; Rees Cosgrove
Journal:  IEEE Trans Med Imaging       Date:  2020-04-21       Impact factor: 10.048

3.  Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial.

Authors:  Aaron E Bond; Binit B Shah; Diane S Huss; Robert F Dallapiazza; Amy Warren; Madaline B Harrison; Scott A Sperling; Xin-Qun Wang; Ryder Gwinn; Jennie Witt; Susie Ro; W Jeffrey Elias
Journal:  JAMA Neurol       Date:  2017-12-01       Impact factor: 18.302

4.  What is the pathway forward for the surgical management of essential tremor?

Authors:  Elan D Louis; Amar Patel; Jason L Gerrard
Journal:  Ann Neurol       Date:  2017-03-15       Impact factor: 10.422

5.  Spatiotemporally-controlled transgene expression in hydroxyapatite-fibrin composite scaffolds using high intensity focused ultrasound.

Authors:  Alexander Moncion; Jonah S Harmon; Yan Li; Sam Natla; Easton C Farrell; Oliver D Kripfgans; Jan P Stegemann; Francisco M Martín-Saavedra; Nuria Vilaboa; Renny T Franceschi; Mario L Fabiilli
Journal:  Biomaterials       Date:  2018-12-13       Impact factor: 12.479

6.  Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.

Authors:  Brian P Mead; Namho Kim; G Wilson Miller; David Hodges; Panagiotis Mastorakos; Alexander L Klibanov; James W Mandell; Jay Hirsh; Jung Soo Suk; Justin Hanes; Richard J Price
Journal:  Nano Lett       Date:  2017-05-18       Impact factor: 11.189

Review 7.  A Comprehensive Review of Brain Connectomics and Imaging to Improve Deep Brain Stimulation Outcomes.

Authors:  Joshua K Wong; Erik H Middlebrooks; Sanjeet S Grewal; Leonardo Almeida; Christopher W Hess; Michael S Okun
Journal:  Mov Disord       Date:  2020-04-12       Impact factor: 10.338

8.  The reduction in treatment efficiency at high acoustic powers during MR-guided transcranial focused ultrasound thalamotomy for Essential Tremor.

Authors:  Alec Hughes; Yuexi Huang; Michael L Schwartz; Kullervo Hynynen
Journal:  Med Phys       Date:  2018-06-01       Impact factor: 4.071

Review 9.  Focused Ultrasound and Other Lesioning Therapies in Movement Disorders.

Authors:  Hannah Walters; Binit B Shah
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-03       Impact factor: 5.081

10.  Is deep brain stimulation therapy underutilized for movement disorders?

Authors:  Aparna Wagle Shukla; Wissam Deeb; Bhavana Patel; Adolfo Ramirez-Zamora
Journal:  Expert Rev Neurother       Date:  2018-11-15       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.